专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20160346385A1 GRANULYSIN IN IMMUNOTHERAPY 有权
公开(公告)号：US20160346385A1
公开(公告)日：2016-12-01
申请号：US15174402
申请日：2016-06-06
申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services
发明人： Alan M. Krensky , Carol Clayberger
IPC分类号： A61K39/39 , A61K45/06 , A61K35/15 , A61K38/20
CPC分类号： A61K39/39 , A61K9/0014 , A61K31/727 , A61K35/15 , A61K35/17 , A61K38/1729 , A61K38/19 , A61K38/2026 , A61K45/06 , A61K2039/55516 , A61K2039/55522 , A61K2039/55527 , C12N5/0639 , C12N5/064 , C12N2501/052 , C12N2501/23 , C12N2501/998 , C12N2506/11 , A61K2300/00
摘要： Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.

72. 发明授权

US09476029B2 Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells 有权
标题翻译：树突状细胞新系谱的体外发育，扩增和体内分析
公开(公告)号：US09476029B2
公开(公告)日：2016-10-25
申请号：US13885025
申请日：2011-11-14
申请人： Lung-Ji Chang
发明人： Lung-Ji Chang
IPC分类号： C12N5/071 , C12N5/00 , C12N5/02 , C12N5/0784 , A61K35/15 , A61K39/00
CPC分类号： C12N5/0639 , A61K35/15 , A61K39/0011 , A61K2039/5154 , A61K2039/5156 , C12N2501/052 , C12N2501/125 , C12N2501/145 , C12N2501/22 , C12N2501/2302 , C12N2501/2304 , C12N2501/2307 , C12N2501/2315 , C12N2501/25 , C12N2501/26 , C12N2510/00
摘要： Disclosed herein are new methods of producing a novel line of dendritic cells. The method comprises subjecting a sample of hematopoietic stem/precursor cells to a first feeder culture system that is supplemented with a first set of factors and a second feeder culture system supplemented with a second group of factors. The disclosure also pertains to new cell types that may be used as cancer immunotherapy.
摘要翻译：本文公开了生产新型树突状细胞系的新方法。该方法包括将造血干/前体细胞的样品经受补充有第一组因子的第一饲养培养系统和补充有第二组因子的第二饲养培养系统。本公开还涉及可用作癌症免疫治疗的新细胞类型。

73. 发明授权

US09399029B2 Immune tolerance inducer 有权
标题翻译：免疫耐受诱导物
公开(公告)号：US09399029B2
公开(公告)日：2016-07-26
申请号：US14413151
申请日：2013-07-03
申请人： SBI PHARMACEUTICALS CO., LTD. , National Center for Child Health and Development
发明人： Tohru Tanaka , Motowo Nakajima , Fuminori Abe , Naomi Haga , Kiwamu Takahashi , Hidenori Ito , Ko Rii
IPC分类号： A61K31/197 , A61K33/26 , C12N5/0784 , A61K38/19 , A61K31/194 , A61K38/40
CPC分类号： A61K31/197 , A61K31/194 , A61K33/26 , A61K38/193 , A61K38/40 , C12N5/064 , C12N2500/24 , C12N2501/052 , C12N2501/22 , C12N2501/2304 , A61K2300/00
摘要： An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-ALA or the derivative and an iron compound as active ingredients is prepared. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
摘要翻译：本发明的目的是提供适用于免疫疾病的治疗的调节性树突状细胞诱导剂以及免疫耐受诱导剂，例如过敏性疾病的预防和/或治疗剂以及预防和/或治疗剂对于自身免疫性疾病，两者都是安全的，并且具有与常规药物不同的作用机制。作为实现上述目的的方法，制备包含5-氨基乙酰丙酸（ALA）或其衍生物或5-ALA或其衍生物和铁化合物的盐作为活性成分的免疫耐受诱导剂。 ALA的优选实例可以包括ALA和各种酯，例如ALA的甲酯，乙酯，丙酯，丁酯和戊酯，以及它们的盐酸盐，磷酸盐和硫酸盐。铁化合物的优选实例可包括柠檬酸亚铁钠。

74. 发明授权

US09303246B2 Methods for producing dendritic cells with an siRNA that interferes with MAPKAPK2 expression 有权
标题翻译：用干扰MAPKAPK2表达的siRNA产生树突状细胞的方法
公开(公告)号：US09303246B2
公开(公告)日：2016-04-05
申请号：US12747759
申请日：2008-12-12
申请人： Thomas Felzmann , Alexander Michael Dohnal
发明人： Thomas Felzmann , Alexander Michael Dohnal
IPC分类号： C12N15/113 , C12N5/0784 , A61K39/00
CPC分类号： C12N5/0639 , A61K2039/5154 , C12N5/064 , C12N2501/052 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/70 , C12N2510/00
摘要： The present invention relates to a method for producing dendritic cells and their use in medicaments by genetic engineering aimed at functionally improving their therapeutic efficacy in the treatment of cancer, microbial infections, allergies, auto-immune diseases or organ and stem cell transplant rejection.
摘要翻译：本发明涉及通过基因工程制备树突状细胞的方法及其在药物中的用途，其目的在于功能上改善其在治疗癌症，微生物感染，过敏，自身免疫疾病或器官和干细胞移植排斥中的治疗功效。

75. 发明申请

US20150352200A1 METHOD FOR PREPARING AN IMMUNOGENIC LYSATE, THE LYSATE OBTAINED, DENDRITIC CELLS LOADED WITH SUCH LYSATE AND A PHARMACEUTICAL COMPOSITION COMPRISING THE LYSATE OR THE DENDRITIC CELLS 有权
标题翻译：制备免疫球蛋白的方法，获得的LYSATE，具有这样的LYSATE的DENDRITIC细胞和包含LYSATE或DENDRITIC细胞的药物组合物
公开(公告)号：US20150352200A1
公开(公告)日：2015-12-10
申请号：US14758153
申请日：2013-12-20
申请人： AMPHERA B.V.
发明人： Josephus Petrus Johannes Jacobus HEGMANS , Joan Geertrudis Jacobus Victor AERTS
IPC分类号： A61K39/00 , C12N5/0784
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/5154 , A61K2039/5158 , A61K2039/6043 , C12N5/0639 , C12N2501/052 , C12N2501/22
摘要： The present invention relates to a method for the preparation of an immunogenic lysate from mesothelioma tumor cells, to such a lysate and to dendritic cells loaded with the lysate, the present invention further relates a pharmaceutical composition comprising such lysate or dendritic cells, to the use of the lysate, and to said loaded dendritic cells or said pharmaceutical composition for use in the prevention or treatment of mesothelioma.
摘要翻译：本发明涉及一种用于从间皮瘤肿瘤细胞，这种裂解物和装载有裂解物的树突状细胞制备免疫原性裂解物的方法，本发明还涉及包含这种裂解物或树突状细胞的药物组合物，的裂解物和所述负载的树突状细胞或所述药物组合物用于预防或治疗间皮瘤。

76. 发明申请

US20150093415A1 ANTIGEN COMPOSITION, PREPARATION METHOD AND USE THEREOF, AND TUMOR VACCINE 有权
标题翻译：抗原组合物，制备方法及其用途及肿瘤疫苗
公开(公告)号：US20150093415A1
公开(公告)日：2015-04-02
申请号：US14394986
申请日：2013-02-04
申请人： National Center for Nanoscience and Technology
发明人： Guangjun Nie , Xin Tian , Motao Zhu
IPC分类号： A61K39/00 , C12N5/0784
CPC分类号： A61K39/0011 , A61K2039/5154 , A61K2039/5158 , C12N5/0639 , C12N2501/052 , C12N2501/22 , C12N2501/2304
摘要： The present invention provides a preparation method of an antigen composition. The preparation method comprises the following steps: (1) obtaining a tumor antigen protein; (2) making the tumor antigen protein into contact with an immature dendritic cell; (3) inducing the immature dendritic cell in contact with the tumor antigen into a mature dendritic cell; and (4) separating a cell vesicle of the mature dendritic cell. The present invention further provides an antigen composition obtained through the preparation method and the application thereof in preparing a tumor vaccine.
摘要翻译：本发明提供抗原组合物的制备方法。制备方法包括以下步骤：（1）获得肿瘤抗原蛋白; （2）使肿瘤抗原蛋白与未成熟树突状细胞接触; （3）将与肿瘤抗原接触的未成熟树突状细胞诱导成成熟树突状细胞; 和（4）分离成熟树突状细胞的细胞囊泡。本发明还提供通过制备方法获得的抗原组合物及其在制备肿瘤疫苗中的应用。

77. 发明申请

US20150023910A1 GRANULYSIN IN IMMUNOTHERAPY 有权
标题翻译：颗粒在免疫学中
公开(公告)号：US20150023910A1
公开(公告)日：2015-01-22
申请号：US14341317
申请日：2014-07-25
申请人： The United States of America, as represented by the Secretary, Department of Health and Human Serv
发明人： Alan M. Krensky , Carol Clayberger
IPC分类号： A61K39/39 , A61K35/14 , A61K45/06 , A61K38/19
CPC分类号： A61K39/39 , A61K9/0014 , A61K31/727 , A61K35/15 , A61K35/17 , A61K38/1729 , A61K38/19 , A61K38/2026 , A61K45/06 , A61K2039/55516 , A61K2039/55522 , A61K2039/55527 , C12N5/0639 , C12N5/064 , C12N2501/052 , C12N2501/23 , C12N2501/998 , C12N2506/11 , A61K2300/00
摘要： Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.
摘要翻译：公开了在宿主中刺激或增强免疫应答的方法。所述方法包括使单核细胞与15kD颗粒溶素接触，从而产生单核细胞衍生的树突状细胞。在一个实例中，该方法还包括使单核细胞或单核细胞衍生的树突状细胞与靶抗原如肿瘤抗原或自身免疫抗原接触。在另一个实施方案中，该方法包括使单核细胞与增强树突状细胞成熟或诱导免疫耐受性的另外的试剂接触。该方法在体内，体外和离体使用。在另一方面，本公开涉及用于治疗肿瘤的组合物和方法。

78. 发明授权

US08815229B2 Granulysin in immunotherapy 有权
标题翻译：颗粒溶素在免疫治疗
公开(公告)号：US08815229B2
公开(公告)日：2014-08-26
申请号：US13501726
申请日：2010-10-08
申请人： Alan M. Krensky , Carol Clayberger
发明人： Alan M. Krensky , Carol Clayberger
IPC分类号： A61K38/17 , C07K14/705
CPC分类号： A61K39/39 , A61K9/0014 , A61K31/727 , A61K35/15 , A61K35/17 , A61K38/1729 , A61K38/19 , A61K38/2026 , A61K45/06 , A61K2039/55516 , A61K2039/55522 , A61K2039/55527 , C12N5/0639 , C12N5/064 , C12N2501/052 , C12N2501/23 , C12N2501/998 , C12N2506/11 , A61K2300/00
摘要： Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.
摘要翻译：公开了在宿主中刺激或增强免疫应答的方法。所述方法包括使单核细胞与15kD颗粒溶素接触，从而产生单核细胞衍生的树突状细胞。在一个实例中，该方法还包括使单核细胞或单核细胞衍生的树突状细胞与靶抗原如肿瘤抗原或自身免疫抗原接触。在另一个实施方案中，该方法包括使单核细胞与增强树突状细胞成熟或诱导免疫耐受性的另外的试剂接触。该方法在体内，体外和离体使用。在另一方面，本公开涉及用于治疗肿瘤的组合物和方法。

79. 发明申请

US20130330310A1 EX VIVO DEVELOPMENT, EXPANSION AND IN VIVO ANALYSIS OF A NOVEL LINEAGE OF DENDRITIC CELLS 有权
标题翻译：新生儿细胞的新发展，扩张和体检分析
公开(公告)号：US20130330310A1
公开(公告)日：2013-12-12
申请号：US13885025
申请日：2011-11-14
申请人： Lung-Ji Chang
发明人： Lung-Ji Chang
IPC分类号： C12N5/0784
CPC分类号： C12N5/0639 , A61K35/15 , A61K39/0011 , A61K2039/5154 , A61K2039/5156 , C12N2501/052 , C12N2501/125 , C12N2501/145 , C12N2501/22 , C12N2501/2302 , C12N2501/2304 , C12N2501/2307 , C12N2501/2315 , C12N2501/25 , C12N2501/26 , C12N2510/00
摘要： Disclosed herein are new methods of producing a novel line of dendritic cells. The method comprises subjecting a sample of hematopoietic stem/precursor cells to a first feeder culture system that is supplemented with a first set of factors and a second feeder culture system supplemented with a second group of factors. The disclosure also pertains to new cell types that may be used as cancer immunotherapy.
摘要翻译：本文公开了生产新型树突状细胞系的新方法。该方法包括将造血干/前体细胞的样品经受补充有第一组因子的第一饲养培养系统和补充有第二组因子的第二饲养培养系统。本公开还涉及可用作癌症免疫治疗的新细胞类型。

80. 发明申请

US20130209422A1 "Pharmaceutical Composition Comprising Stem Cells Treated with NOD2 Agonist or Culture Thereof for Prevention and Treatment of Immune Disorders and Inflammatory Diseases" 有权
标题翻译： “包含用NOD2激动剂治疗的干细胞的药物组合物或其免疫疾病和炎症疾病的预防和治疗”
公开(公告)号：US20130209422A1
公开(公告)日：2013-08-15
申请号：US13818234
申请日：2011-08-19
申请人： Kyung Sun Kang , Hyung Sik Kim
发明人： Kyung Sun Kang , Hyung Sik Kim
IPC分类号： A61K35/28
CPC分类号： A61K35/28 , A61K35/545 , A61K38/05 , C12N5/0665 , C12N2501/02 , C12N2501/05 , C12N2501/052 , C12N2501/054
摘要： The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expression Nucleotide-binding Oligomerization Domain protein 2 (NOD2) with a NOD2 agonist or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a method for preparing PGE2 or TGF-β1 comprising the step of culturing NOD2-expressing stem cells in culture medium with a NOD2 agonist, a graft comprising stem cells expressing NOD2 and the NOD2 agonist, a method for preparing the graft, a composite comprising stem cells expressing NOD2 and the NOD2 agonist, and a culture generated by culturing the NOD2-expressing stem cells with a NOD2 agonist.
摘要翻译：本发明涉及用于预防或治疗免疫疾病和炎性疾病的药物组合物，其包含通过用NOD2激动剂或其培养物培养干细胞表达核苷酸结合寡聚化结构域蛋白2（NOD2）而产生的干细胞。更具体地，本发明涉及一种抑制受试者的免疫应答或炎症反应的方法，包括向受试者施用药物组合物，干细胞或培养物的步骤，制备免疫抑制药物或抗体的方法使用干细胞或其培养物的炎症药物，制备PGE2或TGF-β1的方法，包括用NOD2激动剂培养培养基中培养表达NOD2的干细胞的步骤，包含表达NOD2的干细胞的移植物和NOD2激动剂，制备移植物的方法，包含表达NOD2的干细胞和NOD2激动剂的复合物，以及通过用NOD2激动剂培养表达NOD2的干细胞产生的培养物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式